#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Histopatologická diagnostika kožních melanocytárních lézí


Authors: Lumír Pock;  Alena Skálová
Published in: Čes.-slov. Patol., 60, 2024, No. 1, p. 12-34
Category: Reviews Article

Overview

Melanocytární léze jsou nestabilní tumory, jejichž genom a změny v něm determinují jejich morfologii a biologické vlastnosti. Mezi névy a melanomy jsou v různém smyslu atypické, intermediální léze. Na základě nových molekulárně-biologických poznatků bylo možné v jejich rámci vyčlenit tzv. melanocytomy. Článek poskytuje aktuální souhrn benigních, intermediálních, maligních a kombinovaných melanocytárních kožních lézí a nabízí praktická doporučení při jejich diagnostice.

Klíčová slova:

klasifikace – histopatologie – melanocytární léze – genetické alterace – dermatoskopicko-histopatologické korelace – melanocytomy – praktická diagnostická doporučení – léze intermediální


Sources
  1. Ackley CD, Prieto VG, Bentley RC, Horenstein MG, Seigler HF, Shea CR. Primary chondroid melanoma. J Cutan Pathol 2001; 28: 482-485.
  2. Elder DE, Barnhill RL, Bastian BC et al. Melanocytic neoplasms. In: WHO Classification of Tumours Editorial Board.: Skin Tumours. (Internet: beta version ahead of print. Lyon(France): International Agency for Research on Cancer; 2023. (WHO classification of tumours series, 5th ed.; vol. 12). Availalable from: https://tumourclassification.iarc.who.int/chapters/64
  3. Urso C. Melanocytic skin neoplasms: what lesson from genomic aberrations? Am J Dermatopathol 2019; 4(9): 623-629.
  4. Cohen JN, Yeh I, Mully TW, LeBoit PE, McCalmont TH. Genomic and clinicopathologic characteristics of PRKAR1 A-inactivated melanomas. J Surg Pathol 2020; 44(6): 805-816.
  5. Andea AA. Molecular testing for melanocytic tumors: a practical update. Histopathology; 2022, 80: 150-165.
  6. Tsao H, Bevona C, Goggins W, et al. The transformation rate of moles (melanocytic nevi) into cutaneous melanoma: a population based estimate. Arch Dermatol 2003; 139(3):282-288.
  7. Elder DE, Bastian BC, Cree IA, Massi D, Scolyer RA. The 2018 World health organization classification of cutaneous, mucosal, and uveal melanoma. Arch Pathol Lab Med 2022; 144(4): 500-522.
  8. Shain AH, Yeh I, Kovalyshyn I, et al. The genetic evolution of melanoma from precursor lesions. N Engl J Med 2015; 373,(20): 1926-1936.
  9. Busam Klaus, J. Pathology of Melanocytic Tumors. Available from: Elsevier eBooks+, Elsevier OHCE, 2018.
  10. Massi G, LeBoit PE. Histological diagnosis of nevi and melanoma (2nd ed.). Heidelberg, Springer; 2014: 752 p.
  11. Yeh I, Busam KJ. Spitz melanocytic tumours – a review. Histopathology 2022; 80: 122-134.
  12. McKee PH. Clues to the diagnosis of atypical melanocytic lesions. Histopathology 2010; 56(1): 100-111.
  13. Elmore JG, Barnhill RL, Elder DE et al. Pathologist´s diagnosis of invasive melanoma and melanocytic proliferations: observer accuracy and reproducibility study. BMJ 2017; 28(6): 357.
  14. Lodha S, Daggar S, Celebi JT, et al. Discordance in the diagnosis of difficult melanocytic neoplasms in the clinical settings. J Cutan Pathol. 2008; 35(4): 349-352.
  15. Cerroni L, Barnhill RL, Elder D, et al. Melanocytic tumors of uncertain malignant potential. Results of a tutorial held at the XXIX Symposium of the International Society of Dermatopathology in Graz, October 2008. Am Surg Pathol 2010; 34: 314-326.
  16. Tucker MA, Halpern A, Holly EA, et al. Clinically recognized dysplastic nevi. A central risk factor for cutaneous melanoma. JAMA 1997; 277(18): 1439-1444.
  17. Ebbelaar CF, Schrader AM, van Dijk M, et al. Towards diagnostic criteria for malignant deep penetrating melanocytic tumors using single nucleotide polymorphism array and next-generation sequencing. Mod Pathol 2022; 35(8): 1110-1120.
  18. Zembowicz A, Carney JA, Mihm MC. Pigmented epithelioid melanocytoma: a lowgrade melanocytic tumor with metastatic potential indistinguishable from animal-type melanoma and epithelioid blue nevus. Am J Surg Pathol 2004; 28(1): 31-40.
  19. Donatti M, Martinek P, Steiner P et al. Novel insight into the BAP1-inactivated melanocytic tumor. Mod Pathol 2022; 35: 664-675.
  20. Quan VL., Panah E., Zhang B., et al. The role of gene fusions in melanocytic neoplasms. J Cutan Pathol 2019; 46 (11): 878-887.
  21. Motaparthi K, Kim J, Andea AA, et al. TERT and TERT promoter in melanocytic neoplasms: Current concepts in pathogenesis, diagnosis, and prognosis. J Cutan Pathol 2020; 47 (8): 710-719.
  22. Lallas A, Kyrgidis A, Ferrara G, et al. Atypical Spitz tumours and sentinel lymph node biopsy: a systematic review. Lancet Onco, 2014; 15(4): 178-183.
  23. Pock L. Lentiga a melanocytární névy. In: Pock L, Fikrle T, Drlík L, Zloský P. Dermatoskopický atlas. 2. vyd., Praha: Phlebomedica, 2008: 34-76. ISBN 978-80-901298-5-6.
  24. Pock L, Trnka J, Vosmík F, Záruba F. Systematized Progradient Multiple Combined Melanocytic and Blue Nevus. Am J Dermatopatol 1991; 13(3): 282-287.
  25. Varey AHR, Williams GJ, Lo SN, et al. Clinical management of melanocytic tumours of uncertain malignant potential (MelTUMPs), including melanocytomas: A systematic review and meta-analysis. J Eur Acad Dermatol Venereol 2023; 37(5): 859-870.
  26. Vermariën-wang J, Doeleman T, van Doorn R, et al. Ambiguous melanocytic lesions: A retrospective cohort study of incidence and outcome of melanocytic tumor of uncertain malignant potential (MELTUMP) and superficial atypical melanocytic proliferation of uncertain significance (SAMPUS) in the Netherlands. J Am Acad Dermatol 2023; 88(3): 602-608.
  27. de la Fouchardiere A, Blokx W, van Kempen, LC, et al. ESP, EORTC, AND EURACAN Expert Opinion: practical recommendations for the pathological diagnosis and clinical management of intermediate melanocytic tumors and rare related melanoma variants. Virchows Arch 2021; 479(1): 3-11.
  28. Marsden JR, Newton-Bishop JA, Burrows l, et al.: Revised U.K. guidelines for the management of cutaneous melanoma 2010. Br J Derm 2010; 163: 238-256.
  29. Maurici A, Miceli R, Patuzzo R., et al. Analysis of sentinel node biopsy and clinicopathologic features as prognostic factors in patients with atypical melanocytic tumors. J Natl Compr Canc Netw 2020; 18(10): 1327-1336.
  30. Hosler G.A., Murphy K.M.: Ancillary testing for melanoma: current trends and practical considerations. Human Pathology, ttps://doi. org/10.1016/j.humpatj.2023.05.002. Available online 11 May 2023. In Press.
  31. Lezcano C, Jungbluth AA, Nehal KS, Hollmann TJ, Busam KJ. PRAME Expression in Melanocytic Tumors. Am J Surg Pathol 2018; 42: 1456-1465.
  32. Cesinaro AM, Gallo G, Manfredini S, Maiorana A, Bettelli SR. ROS1 pattern of immunostaining in 11 cases of spitzoid tumour: comparison with histopathological, fluorescence in-situ hybridisation and next-generation sequencing analysis. Histopathology 2021; 79, 966-974.
  33. Alomari AK, Miedema JR, Carter MD et al. DNA copy number changes correlate with clinical behavior in melanocytic neoplasms: proposal of an algorithmic approach. Mod Pathol 2020; 33: 1307-1317.
Labels
Anatomical pathology Forensic medical examiner Toxicology
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#